Daurisoline inhibits glycolysis of lung cancer by targeting the AKT-HK2 axis.

IF 4.4 4区医学 Q2 ONCOLOGY Cancer Biology & Therapy Pub Date : 2025-12-01 Epub Date: 2024-12-19 DOI:10.1080/15384047.2024.2442556

Shi-Ming Tan, Lan Luo, Yi-Fu He, Wei Li, Xin-Xing Wan

引用次数: 0

Abstract

Lung cancer, one of the most prevalent tumors, remains a clinical challenge with a poor five-year survival rate. Daurisoline, a bis-benzylisoquinoline alkaloid derived from the traditional Chinese herb Menispermum dauricum, is known to suppress tumor growth effectively. However, its precise mechanism of action remains unclear. In this study, we demonstrate that Daurisoline targets glycolysis and reduces the protein level of HK2, thereby inhibiting lung cancer progression. Mechanistic investigations reveal that Daurisoline directly binds to AKT and antagonizes the AKT-GSK3β-c-Myc-HK2 signaling axis. Furthermore, in an animal model, we validate the in vivo anti-tumor effect of Daurisoline without any observable side effects. Overall, our findings suggest that Daurisoline holds potential as an anti-tumor agent through its targeting of glycolysis.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Daurisoline通过靶向AKT-HK2轴抑制肺癌糖酵解。

肺癌是最常见的肿瘤之一，其5年生存率很低，仍然是一个临床挑战。Daurisoline是一种双苄基异喹啉生物碱，从传统中药半月草中提取，已知可有效抑制肿瘤生长。然而，其确切的作用机制尚不清楚。在这项研究中，我们证明了Daurisoline靶向糖酵解并降低HK2蛋白水平，从而抑制肺癌的进展。机制研究表明Daurisoline直接结合AKT并拮抗AKT- gsk3 β-c- myc - hk2信号轴。此外，在动物模型中，我们验证了Daurisoline的体内抗肿瘤作用，没有任何可观察到的副作用。总的来说，我们的研究结果表明，Daurisoline通过靶向糖酵解具有抗肿瘤的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Biology & Therapy 医学-肿瘤学

CiteScore

7.00

自引率

0.00%

发文量

审稿时长

2.3 months

期刊介绍： Cancer, the second leading cause of death, is a heterogenous group of over 100 diseases. Cancer is characterized by disordered and deregulated cellular and stromal proliferation accompanied by reduced cell death with the ability to survive under stresses of nutrient and growth factor deprivation, hypoxia, and loss of cell-to-cell contacts. At the molecular level, cancer is a genetic disease that develops due to the accumulation of mutations over time in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Malignant transformation and tumor progression of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. A tremendous amount has been learned about the numerous cellular and molecular genetic changes and the host-tumor interactions that accompany tumor development and progression. It is the goal of the field of Molecular Oncology to use this knowledge to understand cancer pathogenesis and drug action, as well as to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. Cancer Biology & Therapy aims to publish original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We will include timely reviews covering the broad scope of the journal. The journal will also publish op-ed pieces and meeting reports of interest. The goal is to foster communication and rapid exchange of information through timely publication of important results using traditional as well as electronic formats. The journal and the outstanding Editorial Board will strive to maintain the highest standards for excellence in all activities to generate a valuable resource.